US · Healthcare · Drug Manufacturers - General
EPS came in at 2.59 against a street estimate of 2.53 — a beat of 2.4%.
Analysts rate Johnson & Johnson a buy (16 buy, 6 hold, 1 sell out of 23) with an average price target of $279.41.
CONFIDENT Johnson & Johnson delivered 6% operational sales growth, raised 2026 revenue and EPS guidance, while Innovative Medicine strength offset softer MedTech performance and major transaction and litigation costs. Q3 FY26 Worldwide sales were $25.4 billion, with U.S. growth substantially stronger than international growth. Analysts pressed management on MedTech weakness, ICO Tide adoption and the assumptions behind long-term growth. Management emphasized fixing the current MedTech portfolio, strong launch momentum and internal investment rather than relying on M&A. 2026-10-13…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.81% |
| Vanguard Capital Management, LLC | 6.53% |
| State Street Corp | 5.56% |
| Vanguard Portfolio Management, LLC | 2.67% |
| Geode Capital Management, LLC | 2.45% |
| JPMorgan Chase & Co | 2.42% |
| Morgan Stanley - Brokerage Accounts | 1.86% |
| NORGES BANK | 1.32% |
| Document | Date |
|---|---|
| Quarterly report · Q3 FY2027 HEADLINE NUMBERS • Third-quarter 2026 sales were $25,399 million, up from $23,993 million in the third quarter of 2025. • Nine-month 2026 sales were | 2026-10-21 |
| Results announced · Q3 FY2027 HEADLINE NUMBERS • Third-quarter worldwide sales rose 5.9% to $25,399 million from $23,993 million; operational growth was 6.0%. • Nine-month worldw | 2026-10-13 |
| Board / officer change · Q3 FY2027 JOHNSON & JOHNSON FORM 8-K SUMMARY Filed August 4, 2026 --- OTHER NOTABLE POINTS • Executive Leadership Change: Jennifer Taubert announced retireme | 2026-08-04 |
| Reg FD disclosure · Q2 FY2027 JOHNSON & JOHNSON (JNJ) - FORM 8-K SUMMARY Filed: July 29, 2026 --- HEADLINE NUMBERS • 2026 Adjusted Operational EPS guidance reduced to $10.86-$11 | 2026-07-29 |
| Reg FD disclosure · Q2 FY2027 JOHNSON & JOHNSON FORM 8-K SUMMARY July 27, 2026 --- HEADLINE NUMBERS • $5.5 billion total commitment to resolve ovarian talc litigation • $3 billi | 2026-07-28 |
| Quarterly report · Q2 FY2027 JOHNSON & JOHNSON Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Sales (6 months): $49,372 million (up 8.2% vs. $45,636 million prior year) • Sales (Q2): $ | 2026-07-23 |
| Results announced · Q2 FY2027 JOHNSON & JOHNSON Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 Worldwide Sales: $25,310 million (up 6.6% reported, 5.6% operational) • Six-M | 2026-07-15 |
| Quarterly report · Q1 FY2027 JOHNSON & JOHNSON Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Q1 2026 Sales: $24,062 million, up 9.9% from $21,893 million in Q1 2025 • Q1 2026 Net Earn | 2026-04-22 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $1.34 / share ex-date Nov 24, 2026 · pay Dec 8, 2026 | 2026-11-24 |
| Dividend | $1.34 / share ex-date Aug 25, 2026 · pay Sep 8, 2026 | 2026-08-25 |
| Dividend | $1.34 / share ex-date May 26, 2026 · pay Jun 9, 2026 | 2026-05-26 |
| Dividend | $1.30 / share ex-date Feb 24, 2026 · pay Mar 10, 2026 | 2026-02-24 |
| Dividend | $1.30 / share ex-date Nov 25, 2025 · pay Dec 9, 2025 | 2025-11-25 |
| Announcement | Date |
|---|---|
| Completed acquisition of Firefly Bio and strategic collaboration with Sail Johnson & Johnson completed the acquisition of Firefly Bio and entered a strategic collaboration with Sail Biomedicines on July 29, 2026. These transactions require the company to lower its | 2026-07-29 |
| Board declares 3.1% dividend increase, 64th consecutive year Johnson & Johnson reported first-quarter 2026 results on April 14, 2026, and announced a 3.1% dividend increase. The company raised its quarterly dividend from $1.30 to $1.34 per share, brin | 2026-04-14 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Johnson & Johnson — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.